High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Collection:
Health Policy and Services Research
Series Title(s):
Research brief (Leonard Davis Institute of Health Economics)
Author(s):
Doshi, Jalpa A., author
Li, Bengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author
Contributor(s):
Leonard Davis Institute of Health Economics, issuing body.
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
Language(s):
English
Format:
Text
Subject(s):
Cost Sharing
Drug Costs
Medicare Part D -- economics
United States
Genre(s):
Technical Report
Abstract:
KEY FINDINGS: Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not start a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure optimal access to specialty medications under Medicare Part D.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (2 pages))
Illustrations:
Illustrations
NLM Unique ID:
101680603 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101680603